Autoimmune phenomena as prognostic markers of response to adjuvant interferon therapy for melanoma

Puente Vázquez, J; González Larriba, JL

Puente Vázquez, J; González Larriba, JL.

Affiliation

Puente Vázquez, J; s.af
González Larriba, JL; s.af

Clin. transl. oncol. (Print) ; 9(3): 125-126, mar. 2007.

Article in English | IBECS | ID: ibc-123280

Responsible library: ES1.1

Localization: BNCS

Subject(s)

Humans; Autoimmunity; Chemotherapy, Adjuvant/methods; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic/statistics & numerical data; Interferon-alpha/adverse effects; Melanoma/drug therapy; Purpura, Thrombocytopenic, Idiopathic/chemically induced; Purpura, Thrombocytopenic, Idiopathic/complications; Randomized Controlled Trials as Topic; Dose-Response Relationship, Drug; Autoantibodies/blood; Follow-Up Studies; Immune System; Interferon-alpha/administration & dosage; Interferon-alpha/pharmacology; Melanoma/immunology; Melanoma/mortality; Thyrotoxicosis/chemically induced; Vitiligo/chemically induced

Search on Google

Add to My VHL

XML

Collection: National databases / Spain Health context: SDG3 - Target 3.4 Reduce premature mortality due to noncommunicable diseases Health problem: Endocrine System Diseases / Immune Disorders / Melanoma / Other Blood Disorders Database: IBECS Main subject: Autoimmunity / Randomized Controlled Trials as Topic / Purpura, Thrombocytopenic, Idiopathic / Interferon-alpha / Chemotherapy, Adjuvant / Clinical Trials, Phase III as Topic / Melanoma Type of study: Controlled clinical trial / Observational study / Prognostic study / Risk factors Limits: Humans Language: English Journal: Clin. transl. oncol. (Print) Year: 2007 Document type: Article

Search on Google

Add to My VHL

XML